Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.068
Abstract: Abstract Background ABSSSIs are common in patients with diabetes and have an increased risk of complications. Dalbavancin is a long-acting lipoglycopeptide with potent activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA),… read more here.
Keywords: patients diabetes; allergan plc; plc employee; skin ... See more keywords